TY  - JOUR
AU  - Barrero, Francisco
AU  - Mallada-Frechin, Javier
AU  - Martínez-Ginés, María Luisa
AU  - Marzo, María Eugenia
AU  - Meca-Lallana, Virginia
AU  - Izquierdo, Guillermo
AU  - Ara, José Ramón
AU  - Oreja-Guevara, Celia
AU  - Meca-Lallana, José
AU  - Forero, Lucía
AU  - Sánchez-Vera, Irene
AU  - Moreno, María José
AU  - in representation of the MS NEXT study investigators
PY  - 2020
DO  - 10.1371/journal.pone.0230846
UR  - http://hdl.handle.net/10668/15312
T2  - PloS one
AB  - The objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice. This observational, retrospective, multicentre,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Disabled Persons
KW  - Female
KW  - Fingolimod Hydrochloride
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Natalizumab
KW  - Recurrence
KW  - Retrospective Studies
KW  - Spain
TI  - Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
TY  - research article
VL  - 15
ER  -